Description: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Home Page: www.kymeratx.com
KYMR Technical Analysis
200 Arsenal Yards Boulevard
Watertown,
MA
02472
United States
Phone:
857 285 5300
Officers
| Name | Title |
|---|---|
| Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. | Co-Founder & Chairman |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Ms. Elaine Caughey | Chief Bus. Officer |
| Kevin Dushney | Sr. VP of IT & Operations |
| Mr. Michael J. Todisco | VP of Accounting & Fin. |
| Mr. Vijay Sabesan | Sr. VP of Technical Operations |
| Ms. Melissa Brody | VP of Bus. Devel. |
| Ms. Karen Weisbach | VP of People & Culture |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1685 |
| Price-to-Sales TTM: | 33.3041 |
| IPO Date: | 2020-08-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 169 |